Why the study?
NAFLD is an increasing health burden where only a minority progress to advanced disease, presenting a challenge for early identification of at-risk patients.
Genetic risk scores combining variants like PNPLA3, TM6SF2, and HSD17B13 with clinical parameters may enable early identification of NAFLD patients at risk of progression to advanced liver disease.
May refine NAFLD prognostication; leaves open prospective validation before clinical adoption.
PURPOSE OF REVIEW: Non-alcoholic fatty liver disease (NAFLD) is a major and increasing health burden, with the potential to overwhelm hepatology services. However, only a minority of patients develop advanced liver disease. The challenge is early identification of patients at risk of progression. This review aims to summarize current knowledge on the genetic predisposition to NAFLD, and its implications for prognostication and risk stratification. RECENT FINDINGS: PNPLA3-I148M is the most robustly associated genetic variant with NAFLD. Recently, variants in TM6SF2, MBOAT7, GCKR and HSD17B13 have also been implicated. NAFLD is a complex disease, and any one genetic variant alone is insufficient for risk stratification, but combining multiple genetic variants with other parameters is a promising strategy. It is anticipated that, in the near future, analysis of data from large-scale prospective cohorts will reveal NAFLD subtypes and enable the development of prognostic models. This will facilitate risk stratification of patients, enabling optimisation of resources to effectively manage the NAFLD epidemic.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: